These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 22353243)

  • 61. Fragment-based lead discovery: a chemical update.
    Erlanson DA
    Curr Opin Biotechnol; 2006 Dec; 17(6):643-52. PubMed ID: 17084612
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Target immobilization as a strategy for NMR-based fragment screening: comparison of TINS, STD, and SPR for fragment hit identification.
    Kobayashi M; Retra K; Figaroa F; Hollander JG; Ab E; Heetebrij RJ; Irth H; Siegal G
    J Biomol Screen; 2010 Sep; 15(8):978-89. PubMed ID: 20817886
    [TBL] [Abstract][Full Text] [Related]  

  • 63. NMR characterization of RNA small molecule interactions.
    Thompson RD; Baisden JT; Zhang Q
    Methods; 2019 Sep; 167():66-77. PubMed ID: 31128236
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Design and synthesis of a mitochondria-targeting carrier for small molecule drugs.
    Han J; Lee TH; Tung CH; Lee DY
    Org Biomol Chem; 2014 Dec; 12(48):9793-6. PubMed ID: 25378226
    [TBL] [Abstract][Full Text] [Related]  

  • 65. SAR by ILOEs: an NMR-based approach to reverse chemical genetics.
    Becattini B; Pellecchia M
    Chemistry; 2006 Mar; 12(10):2658-62. PubMed ID: 16121405
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Identification of specific small molecule ligands for stem loop 3 ribonucleic acid of the packaging signal Psi of human immunodeficiency virus-1.
    Warui DM; Baranger AM
    J Med Chem; 2009 Sep; 52(17):5462-73. PubMed ID: 19691339
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Towards structure-based protein drug design.
    Zhang C; Lai L
    Biochem Soc Trans; 2011 Oct; 39(5):1382-6, suppl 1 p following 1386. PubMed ID: 21936819
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Introduction to fragment-based drug discovery.
    Erlanson DA
    Top Curr Chem; 2012; 317():1-32. PubMed ID: 21695633
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Structure-guided fragment screening for lead discovery.
    Verdonk ML; Hartshorn MJ
    Curr Opin Drug Discov Devel; 2004 Jul; 7(4):404-10. PubMed ID: 15338949
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Druggable pockets and binding site centric chemical space: a paradigm shift in drug discovery.
    Pérot S; Sperandio O; Miteva MA; Camproux AC; Villoutreix BO
    Drug Discov Today; 2010 Aug; 15(15-16):656-67. PubMed ID: 20685398
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Kinase inhibitor data modeling and de novo inhibitor design with fragment approaches.
    Vieth M; Erickson J; Wang J; Webster Y; Mader M; Higgs R; Watson I
    J Med Chem; 2009 Oct; 52(20):6456-66. PubMed ID: 19791746
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Targeting serpins in high-throughput and structure-based drug design.
    Chang YP; Mahadeva R; Patschull AO; Nobeli I; Ekeowa UI; McKay AR; Thalassinos K; Irving JA; Haq I; Nyon MP; Christodoulou J; Ordóñez A; Miranda E; Gooptu B
    Methods Enzymol; 2011; 501():139-75. PubMed ID: 22078534
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Multicomponent reaction design in the quest for molecular complexity and diversity.
    Ruijter E; Scheffelaar R; Orru RV
    Angew Chem Int Ed Engl; 2011 Jul; 50(28):6234-46. PubMed ID: 21710674
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Virtual screening of compound libraries.
    Cerqueira NM; Sousa SF; Fernandes PA; Ramos MJ
    Methods Mol Biol; 2009; 572():57-70. PubMed ID: 20694685
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Informatics and modeling challenges in fragment-based drug discovery.
    Hubbard RE; Chen I; Davis B
    Curr Opin Drug Discov Devel; 2007 May; 10(3):289-97. PubMed ID: 17554855
    [TBL] [Abstract][Full Text] [Related]  

  • 76. NMR-guided fragment-based approach for the design of AAC(6')-Ib ligands.
    Lombès T; Bégis G; Maurice F; Turcaud S; Lecourt T; Dardel F; Micouin L
    Chembiochem; 2008 Jun; 9(9):1368-71. PubMed ID: 18464231
    [No Abstract]   [Full Text] [Related]  

  • 77. Docking methods for structure-based library design.
    Cavasotto CN; Phatak SS
    Methods Mol Biol; 2011; 685():155-74. PubMed ID: 20981523
    [TBL] [Abstract][Full Text] [Related]  

  • 78. NMR quantification of H-bond donating ability for bioactive functional groups and isosteres.
    Jennings JJ; Milic M; Targos K; Franz AK
    Eur J Med Chem; 2020 Dec; 207():112693. PubMed ID: 32862126
    [TBL] [Abstract][Full Text] [Related]  

  • 79. RNA as a small molecule druggable target.
    Rizvi NF; Smith GF
    Bioorg Med Chem Lett; 2017 Dec; 27(23):5083-5088. PubMed ID: 29097169
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Understanding Molecular Drivers of Melanin Binding To Support Rational Design of Small Molecule Ophthalmic Drugs.
    Jakubiak P; Reutlinger M; Mattei P; Schuler F; Urtti A; Alvarez-Sánchez R
    J Med Chem; 2018 Nov; 61(22):10106-10115. PubMed ID: 30398862
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.